Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Cohorts 1 and 2: chronic genotype 1 or 3 HCV infection~* Cohort 3: chronic genotype 1 or 4 HCV infection~* HCV RNA ≥ 10\^4 IU/mL at screening~* Screening labs within defined thresholds~* Cirrhosis determination at screening~Key Exclusion Criteria:~* Females who are pregnant or nursing or males who have a pregnant partner~* Prior null response to pegylated interferon (Peg-IFN)+RBV therapy (Cohorts 1 and 2) or for individuals with cirrhosis, prior treatment failure with IFN-based therapy not resulting from treatment intolerance (Cohort 3)~* Current of prior history of hepatic decompensation~* Infection with hepatitis B virus (HBV) or HIV~* History of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with individual's treatment and/or adherence to the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF 200 mg + RBV 200 mg (Cohort 1) (Type: EXPERIMENTAL): Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
- SOF 400 mg + RBV 200 mg (Cohort 2) (Type: EXPERIMENTAL): Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
- LDV/SOF (Cohort 3) (Type: EXPERIMENTAL): Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).